Yuqing Chen - Shanghai Fosun Senior Vice President
| SFOSFDelisted Stock | USD 1.70 0.00 0.00% |
President
Yuqing Chen is Senior Vice President of Shanghai Fosun Pharmaceutical
| Age | 48 |
| Phone | 86 21 3398 7000 |
| Web | https://www.fosunpharma.com |
Shanghai Fosun Management Efficiency
The company has return on total asset (ROA) of 0.0204 % which means that it generated a profit of $0.0204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0756 %, meaning that it generated $0.0756 on every $100 dollars invested by stockholders. Shanghai Fosun's management efficiency ratios could be used to measure how well Shanghai Fosun manages its routine affairs as well as how well it operates its assets and liabilities.Shanghai Fosun Pharmaceutical has accumulated 9.05 B in total debt with debt to equity ratio (D/E) of 0.64, which is about average as compared to similar companies. Shanghai Fosun Pharm has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Shanghai Fosun until it has trouble settling it off, either with new capital or with free cash flow. So, Shanghai Fosun's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Shanghai Fosun Pharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Shanghai to invest in growth at high rates of return. When we think about Shanghai Fosun's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Parker Javid | Lifecore Biomedical | 55 | |
| Rade Kovacevic | Canopy Growth Corp | 33 | |
| Ricky Hopson | Catalent | 48 | |
| Alessandro Maselli | Catalent | 52 | |
| Aristippos Gennadios | Catalent | 58 | |
| Andre Jerome | Aurora Cannabis | N/A | |
| Steve Dobler | Aurora Cannabis | 54 | |
| Wetteny Joseph | Catalent | 48 | |
| CPA CMA | Tilray Inc | N/A | |
| Charles Lickfold | Catalent | 50 | |
| Jonathan Arnold | Catalent | 54 | |
| Carey Squires | Aurora Cannabis | N/A | |
| Dave Paterson | Canopy Growth Corp | N/A | |
| Trish Hunt | Catalent | 54 | |
| Ty Gilmore | Tilray Inc | N/A | |
| MD MBA | Shuttle Pharmaceuticals | 55 | |
| Tom PEng | Catalent | 56 | |
| Mike Lee | Canopy Growth Corp | 47 | |
| Steven Fasman | Catalent | 57 | |
| Scott Gunther | Catalent | 52 | |
| Darren Karasiuk | Aurora Cannabis | N/A | |
Management Performance
| Return On Equity | 0.0756 | |||
| Return On Asset | 0.0204 |
Shanghai Fosun Pharm Leadership Team
Elected by the shareholders, the Shanghai Fosun's board of directors comprises two types of representatives: Shanghai Fosun inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shanghai. The board's role is to monitor Shanghai Fosun's management team and ensure that shareholders' interests are well served. Shanghai Fosun's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shanghai Fosun's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kexin Wang, Vice President | ||
| Shengli Li, Ex Pres | ||
| Deyong Wen, Vice President | ||
| Yuqing Chen, Senior Vice President | ||
| Jia Yan, Director Department | ||
| Jingping Mei, Vice President | ||
| Aimin Hui, Senior Vice President | ||
| Xiaolei Wu, VP CFO | ||
| Xiaohui Guan, CFO and Sr. VP | ||
| Yifang Wu, President CEO |
Shanghai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Shanghai Fosun a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0756 | |||
| Return On Asset | 0.0204 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 15.52 B | |||
| Shares Outstanding | 551.94 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 35.60 % | |||
| Price To Earning | 13.80 X | |||
| Price To Book | 1.45 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Shanghai Pink Sheet
If you are still planning to invest in Shanghai Fosun Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shanghai Fosun's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |